U.S. markets close in 5 hours 23 minutes
  • S&P 500

    3,457.08
    +13.96 (+0.41%)
     
  • Dow 30

    28,401.99
    +93.20 (+0.33%)
     
  • Nasdaq

    11,569.96
    +53.46 (+0.46%)
     
  • Russell 2000

    1,620.35
    +2.65 (+0.16%)
     
  • Crude Oil

    40.99
    -0.71 (-1.70%)
     
  • Gold

    1,931.40
    +16.00 (+0.84%)
     
  • Silver

    25.33
    +0.35 (+1.40%)
     
  • EUR/USD

    1.1884
    +0.0055 (+0.46%)
     
  • 10-Yr Bond

    0.8130
    +0.0160 (+2.01%)
     
  • GBP/USD

    1.3160
    +0.0213 (+1.65%)
     
  • USD/JPY

    104.3700
    -1.1000 (-1.04%)
     
  • BTC-USD

    12,722.75
    +1,665.74 (+15.07%)
     
  • CMC Crypto 200

    254.36
    +9.47 (+3.87%)
     
  • FTSE 100

    5,804.53
    -84.69 (-1.44%)
     
  • Nikkei 225

    23,639.46
    +72.42 (+0.31%)
     

Tenet Healthcare Corporation (NYSE:THC) Shares Could Be 38% Below Their Intrinsic Value Estimate

Simply Wall St
·6 mins read

In this article we are going to estimate the intrinsic value of Tenet Healthcare Corporation (NYSE:THC) by taking the forecast future cash flows of the company and discounting them back to today's value. We will take advantage of the Discounted Cash Flow (DCF) model for this purpose. There's really not all that much to it, even though it might appear quite complex.

Companies can be valued in a lot of ways, so we would point out that a DCF is not perfect for every situation. Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model.

See our latest analysis for Tenet Healthcare

The model

We use what is known as a 2-stage model, which simply means we have two different periods of growth rates for the company's cash flows. Generally the first stage is higher growth, and the second stage is a lower growth phase. To start off with, we need to estimate the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.

Generally we assume that a dollar today is more valuable than a dollar in the future, so we need to discount the sum of these future cash flows to arrive at a present value estimate:

10-year free cash flow (FCF) forecast

2021

2022

2023

2024

2025

2026

2027

2028

2029

2030

Levered FCF ($, Millions)

US$532.8m

US$1.22b

US$895.4m

US$736.3m

US$649.7m

US$600.5m

US$572.6m

US$557.9m

US$551.5m

US$550.8m

Growth Rate Estimate Source

Analyst x4

Analyst x2

Est @ -26.33%

Est @ -17.77%

Est @ -11.77%

Est @ -7.57%

Est @ -4.64%

Est @ -2.58%

Est @ -1.14%

Est @ -0.13%

Present Value ($, Millions) Discounted @ 14%

US$466

US$931

US$601

US$432

US$334

US$270

US$225

US$192

US$166

US$145

("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = US$3.8b

We now need to calculate the Terminal Value, which accounts for all the future cash flows after this ten year period. For a number of reasons a very conservative growth rate is used that cannot exceed that of a country's GDP growth. In this case we have used the 5-year average of the 10-year government bond yield (2.2%) to estimate future growth. In the same way as with the 10-year 'growth' period, we discount future cash flows to today's value, using a cost of equity of 14%.

Terminal Value (TV)= FCF2030 × (1 + g) ÷ (r – g) = US$551m× (1 + 2.2%) ÷ (14%– 2.2%) = US$4.7b

Present Value of Terminal Value (PVTV)= TV / (1 + r)10= US$4.7b÷ ( 1 + 14%)10= US$1.2b

The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is US$5.0b. To get the intrinsic value per share, we divide this by the total number of shares outstanding. Compared to the current share price of US$29.6, the company appears quite good value at a 38% discount to where the stock price trades currently. Valuations are imprecise instruments though, rather like a telescope - move a few degrees and end up in a different galaxy. Do keep this in mind.

dcf
dcf

Important assumptions

We would point out that the most important inputs to a discounted cash flow are the discount rate and of course the actual cash flows. You don't have to agree with these inputs, I recommend redoing the calculations yourself and playing with them. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Tenet Healthcare as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 14%, which is based on a levered beta of 2.000. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.

Next Steps:

Valuation is only one side of the coin in terms of building your investment thesis, and it shouldn't be the only metric you look at when researching a company. The DCF model is not a perfect stock valuation tool. Instead the best use for a DCF model is to test certain assumptions and theories to see if they would lead to the company being undervalued or overvalued. If a company grows at a different rate, or if its cost of equity or risk free rate changes sharply, the output can look very different. Can we work out why the company is trading at a discount to intrinsic value? For Tenet Healthcare, we've put together three pertinent aspects you should consider:

  1. Risks: Every company has them, and we've spotted 1 warning sign for Tenet Healthcare you should know about.

  2. Future Earnings: How does THC's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.

  3. Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!

PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the NYSE every day. If you want to find the calculation for other stocks just search here.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.